Biocon gets approval for diabetes drug Liraglutide in India

The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus

SeQuent–Viyash merger receives stock exchange approvals; NCLT filing underway

QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25

Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25

Alkem reports 7.1% YoY revenue growth in Q4 FY25

Annual EBITDA margin expands by 170 basis points

Procter & Gamble Hygiene and Health Care posts Q3 FY25 PAT at Rs. 156 Cr

The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago

Pimicotinib demonstrates best-in-class potential with significant efficacy and clinically meaningful improvements in patients with tenosynovial giant cell tumor

MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume

Kerala Ayurveda reports FY25 consolidated revenue higher by 22% at Rs. 137.2 Cr

Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year

Granules India posts Q4 FY25 PAT at Rs. 152 Cr

The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility

Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr

For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore

Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr

During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore